Geode Capital Management LLC Purchases 88,183 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)

Geode Capital Management LLC grew its position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 17.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 605,191 shares of the company’s stock after purchasing an additional 88,183 shares during the quarter. Geode Capital Management LLC’s holdings in SELLAS Life Sciences Group were worth $757,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Renaissance Technologies LLC bought a new stake in SELLAS Life Sciences Group during the second quarter valued at $39,000. State Street Corp lifted its stake in shares of SELLAS Life Sciences Group by 30.2% in the 3rd quarter. State Street Corp now owns 174,529 shares of the company’s stock valued at $218,000 after purchasing an additional 40,500 shares during the period. XTX Topco Ltd bought a new stake in shares of SELLAS Life Sciences Group during the 3rd quarter valued at about $78,000. Finally, Anson Funds Management LP acquired a new stake in SELLAS Life Sciences Group during the third quarter worth approximately $992,000. 17.38% of the stock is currently owned by institutional investors and hedge funds.

SELLAS Life Sciences Group Stock Performance

Shares of SLS stock opened at $0.95 on Friday. SELLAS Life Sciences Group, Inc. has a fifty-two week low of $0.50 and a fifty-two week high of $1.72. The stock has a 50 day simple moving average of $1.08 and a two-hundred day simple moving average of $1.17. The company has a market cap of $67.04 million, a P/E ratio of -1.38 and a beta of 2.41.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.